Probing lung microstructure with hyperpolarized noble gas diffusion MRI: theoretical models and experimental results.
Probing lung microstructure with hyperpolarized noble gas diffusion MRI: theoretical models and experimental results.
复制标题
DOI：
10.1002/mrm.24729
复制
发表时间：
2014-03
影响因子：
3.3
通讯作者：
Conradi MS
中科院分区：
文献类型：
--
作者：
Yablonskiy DA;Sukstanskii AL;Quirk JD;Woods JC;Conradi MS
超极化气体(3He和129Xe)的引入为气体试剂特别适合的应用打开了大门-肺磁共振。其中一种肺部应用，扩散磁共振成像，依赖于测量吸入的超极化气体原子在肺空气中扩散的布朗运动。在这篇文章中，我们概述了超极化气体扩散磁共振成像背后的理论思想和十年来所取得的研究成果。我们描述了一种基于测量气体表观扩散系数(ADC)的简单技术和一种先进的技术-活体肺形态计量术，该技术根据Webel参数(腺泡气道半径和肺泡深度)和标准指标(平均线性截距、表面积体积比和肺泡密度)来量化肺微观结构，这些指标被肺部研究人员广泛使用，但以前只能通过有创肺活检获得。这项技术能够从不到15次的S磁共振扫描中提供关于肺微结构的独特的三维断层信息，结果与直接组织学测量结果非常一致。这些安全和灵敏的扩散测量提高了我们对健康和疾病中肺结构和功能的了解，为临床试验中监测治疗干预的有效性提供了一个平台。
The introduction of hyperpolarized gases (3He and 129Xe) has opened the door to applications for which gaseous agents are uniquely suited–lung MRI. One of the pulmonary applications, diffusion MRI, relies on measuring Brownian motion of inhaled hyperpolarized gas atoms diffusing in lung airspaces. In this article we provide an overview of the theoretical ideas behind hyperpolarized gas diffusion MRI and the results obtained over the decade-long research. We describe a simple technique based on measuring gas apparent diffusion coefficient (ADC) and an advanced technique, in vivo lung morphometry, that quantifies lung microstructure both in terms of Weibel parameters (acinar airways radii and alveolar depth) and standard metrics (mean linear intercept, surface-to-volume ratio, and alveolar density) that are widely used by lung researchers but were previously available only from invasive lung biopsy. This technique has the ability to provide unique three-dimensional tomographic information on lung microstructure from a less than 15 s MRI scan with results that are in good agreement with direct histological measurements. These safe and sensitive diffusion measurements improve our understanding of lung structure and functioning in health and disease, providing a platform for monitoring the efficacy of therapeutic interventions in clinical trials.
登录
查看更多内容
影响因子：
3.3
作者：
Boudreau, Mathieu;Xu, Xiaojun;Santyr, Giles E.
通讯作者：
Santyr, Giles E.
影响因子：
4.8
作者：
Diaz, Sandra;Casselbrant, Ingrid;Akeson, Per
通讯作者：
Akeson, Per
DOI：
10.1164/ajrccm.159.3.9805067
发表时间：
1999-03-01
影响因子：
24.7
作者：
Coxson, HO;Rogers, RM;Hogg, JC
通讯作者：
Hogg, JC
影响因子：
3.3
作者：
Diaz, Sandra;Casselbrant, Ingrid;Akeson, Per
通讯作者：
Akeson, Per
影响因子：
2.2
作者：
Bidinosti, CP;Choukeife, J;Tastevin, G
通讯作者：
Tastevin, G